Replies to post #4435 on Dendreon Corp fka DNDNQ

[walldiver]

That Phase 2 was held at either one trial site (Johns Hopkins) or the JH site and one other. There are also have been rumors circulated that JH cherry-picked the enrollees, which is a frequent occurrence in earlier-stage trials. CEGE admitted last year that they were expanding VITAL-1 beyond Western Europe because of slow enrollment. It may be true that the goal for the injections is to limit them to two per visit, but it's been mentioned by more than one source that most patients need 16 injections per visit. There is also strict prohibition of crossovers from one arm to the other. This non-crossover component has played a large part in the slow enrollment. Some people don't want to be prevented from receiving Taxotere if they wind up in the experimental arm, so they don't enroll. Others don't want to take the chance of not being able to receive the vaccine, so they don't enroll.